The data, presented at the 17th IASLC World Conference on Lung Cancer in , showed nintedanib plus pemetrexed/cisplatin demonstrated a meaningful clinical benefit compared to placebo plus pemetrexed/cisplatin, with a significantly improved PFS . Preliminary overall survival data also favored nintedanib .
